| apixaban versus aspirin | |||
| AVERROES, 2011 NCT00496769 | apixaban 5 mg (or 2.5 mg) twice daily versus aspirin 81-324 md daily | patients with atrial fibrillation who have failed or are unsuitable for vitamin K antagonist treatment | double blind Follow-up duration: maximum 21 months 36 countries |
| aspirin versus placebo | |||
| SPAF (aspirin,warfarin ineligible arm), 1991 | aspirin 325mg/d
versus placebo | nonrheumatic atrial fibrillation, warfarin ineligible patients | Double blind Follow-up duration: 1.3 years USA |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
